← Back to Home
Tirzepatide
RxCUI 261551peptideGIP/GLP-1 receptor agonist
Dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
Regulatory status
FDA approved. Application NDA215866.
Evidence
Supported by 28 clinical studies.
Classification
GIP/GLP-1 receptor agonist
Mechanism
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that improves glycemic control and supports weight loss.
Uses
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; and for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
Safety
Contraindicated in personal or family history of MTC or MEN 2. Risk of thyroid C-cell tumors. Pancreatitis, gallbladder disease, and acute kidney injury have been reported.
Tags
metabolicendocrine